Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC

被引：0
|
作者：
Janne, Pasi A.
Mostillo, Joseph
Shrestha, Pomy
Zhang, Ruoyang
Fan, Pang-Dian
Cantero, Frederique
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[4] Daiichi Sankyo, Basking Ridge, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3161
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
    Steuer, Conor Ernst
    Hayashi, Hidetoshi
    Su, Wu-Chou
    Nishio, Makoto
    Johnson, Melissa Lynne
    Kim, Dong-Wan
    Koczywas, Marianna
    Felip, Enriqueta
    Gold, Kathryn A.
    Murakami, Haruyasu
    Baik, Christina S.
    Kim, Sang-We
    Smit, Egbert F.
    Gigantone, Mark
    Kim, Ben
    Fan, Pang-Dian
    Qi, Zhenhao
    Wu, Elaine Y.
    Sternberg, David W.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
    Johnson, M. L.
    Steuer, C. E.
    Hayashi, H.
    Su, W. -C.
    Nishio, M.
    Kim, D. -W.
    Koczywas, M.
    Felip, E.
    Gold, K. A.
    Murakami, H.
    Baik, C. S.
    Kim, S. -W.
    Smit, E. F.
    Gigantone, M.
    Kim, B.
    Fan, P. -D.
    Qi, Z.
    Wu, E. Y.
    Sternberg, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
  • [23] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Vigliotti, M.
    Shipitofsky, N.
    Singh, J.
    Guevara, F.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2290 - S2290
  • [24] Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC
    Janne, P.
    Yu, H.
    Johnson, M.
    Steuer, C.
    Vigliotti, M.
    Shipitofsky, N.
    Guevara, F. M.
    Chen, S.
    Yu, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S815 - S816
  • [25] Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC
    Janne, Pasi A.
    Yu, Helena Alexandra
    Johnson, Melissa Lynne
    Vigliotti, Michele
    Shipitofsky, Nicole
    Guevara, Ferdinand Morales
    Chen, Shuquan
    Yu, Channing
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI
    Mok, Tony
    Jaenne, Pasi A.
    Nishio, Makoto
    Novello, Silvia
    Reck, Martin
    Steuer, Conor
    Wu, Yi-Long
    Fougeray, Ronan
    Fan, Pang-Dian
    Meng, Jie
    Sternberg, David W.
    Esker, Stephen
    Yu, Helena A.
    FUTURE ONCOLOGY, 2024, 20 (15) : 969 - 980
  • [27] Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2-advanced breast cancer (ABC)
    Pistilli, B.
    Pierotti, L.
    Lacroix-Triki, M.
    Vicier, C.
    Frenel, J-S.
    D'Hondt, V.
    Dalenc, F.
    Bachelot, T.
    Ducoulombier, A.
    Benderra, M-A.
    Loirat, D.
    Mayeur, D.
    Nachabeh, G. B.
    Sporchia, A.
    Suto, F.
    Michiels, S.
    Corcos, N.
    Mosele, M. F.
    Andre, F.
    Montagnac, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S357 - S357
  • [28] A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
    Goto, K.
    Hida, T.
    Funami, N.
    Iwasawa, R.
    Mita, S.
    Botilde, Y.
    Yamashita, A.
    Inoh, Y.
    Haddish-Berhane, N.
    Xie, J.
    Roshak, A.
    Knoblauch, R. E.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S344 - S345
  • [29] SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer
    Oliveira, M.
    Cejalvo Andujar, J. M.
    Margeli Vila, M.
    Tolosa Ortega, P.
    Martinez Saez, O.
    Salvador Bofill, F. J.
    Cruz Jurado, J.
    Barrera, A. M. Luna
    Arumi De Dios, M. A.
    Vidal Losada, M. J.
    Guerra, J. A.
    Pernas Simon, S.
    Villacampa Javierre, G.
    Gonzalez-Farre, B.
    Sanfeliu Torres, E.
    Santhanagopal, A.
    Falato, C.
    Ferrero Cafiero, J. M.
    Pascual, T.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S628 - S628
  • [30] HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI
    Halmos, B.
    Yu, H.
    Wu, Y. -L.
    Nishio, M.
    Reck, M.
    Wu, E.
    Sternberg, D.
    Esker, S.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E30
12345